| __timestamp | Bristol-Myers Squibb Company | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 79383000 |
| Thursday, January 1, 2015 | 5001000000 | 108402000 |
| Friday, January 1, 2016 | 5002000000 | 46928000 |
| Sunday, January 1, 2017 | 4849000000 | 74959000 |
| Monday, January 1, 2018 | 4551000000 | 79716000 |
| Tuesday, January 1, 2019 | 4871000000 | 74669000 |
| Wednesday, January 1, 2020 | 7661000000 | 59040000 |
| Friday, January 1, 2021 | 7690000000 | 77417000 |
| Saturday, January 1, 2022 | 7814000000 | 91473000 |
| Sunday, January 1, 2023 | 7772000000 | 94314000 |
| Monday, January 1, 2024 | 8414000000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Bristol-Myers Squibb Company (BMY) and MannKind Corporation (MNKD) offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Bristol-Myers Squibb's SG&A expenses have shown a consistent upward trend, peaking in 2022 with a 37% increase from 2014. This growth reflects the company's strategic investments in marketing and administration to maintain its competitive edge.
Conversely, MannKind Corporation's SG&A expenses have remained relatively stable, with a modest 19% increase over the same period. This stability suggests a more conservative approach, focusing on cost efficiency while navigating the challenges of the biotech sector.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs MannKind Corporation Trends and Insights
MannKind Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
MannKind Corporation and Dynavax Technologies Corporation: SG&A Spending Patterns Compared